Background: Ischemia is a multifactorial disorder in which several genetic and
environmental factors are involved. Platelets are the major causative agents of this disease because
their elevated activity and aggregation would increase the risk of atherosclerosis and thrombosis, as
well as ischemia. A number of polymorphisms in platelet receptors can increase the risk of ischemia
and single-nucleotide polymorphisms (SNPs) have been detected in platelets. In addition,
polymorphisms in other genes have been shown to cause platelet adhesion and aggregation that
plays a role in ischemia. Patients respond differently to anti-platelet drugs which are used to treat
patients with ischemia. Polymorphisms affect patients' responses to anti-platelet drugs, for instance,
by increasing platelet activity and causing resistance of platelets to these drugs. Diagnosis of these
polymorphisms can greatly contribute to better prediction of prognosis and response to treatment of
patients, leading to more effective therapeutic strategies and a proper approach to ischemia.
Conclusion: In this review, we have evaluated the role of polymorphisms involved in platelet
activation and development of ischemia.
Keywords: Platelet, polymorphisms, ischemia, cardiovascular, atherosclerotic plaque, glycoproteins, diabetes, obesity.
Rights & PermissionsPrintExport